Applications close Wednesday! The 2027 IPC International Fellowship Program pairs early-career dermatologists and researchers with an #IPCBoard Member or #IPCCouncilor for a year of clinical or research mentorship. Apply by September 30: psoriasiscouncil.org/educati… #IPCFellowship

If a drug clears the skin, does it help the rest of the body, too? #IPCCouncilor Georg Stingl challenges a common assumption in psoriasis care, presenting data showing that some of the most effective biologics for skin clearance can worsen lipid levels: psoriasiscouncil.org/resourc…

Save the date! The 11th International Congress, Psoriasis: from Gene to Clinic, returns to London, December 2–4, 2027. Held every three years since 1996, it links psoriasis science and patient care. Program details coming soon: psoriasisg2c.com/ #Psoriasis #Dermatology

Psoriasis care extends beyond the skin. A new IPC paper in 𝘑𝘈𝘈𝘋 sets out five priorities for cardiometabolic screening and care. Free slides to share with colleagues: psoriasiscouncil.org/wp-cont… #Psoriasis #Comorbidity

Applications for the 2027 IPC International Fellowship Program close Sept. 30, 2026. Early-career dermatologists and researchers: 12 months of mentorship with an IPC Board Member or Councilor. Apply: psoriasiscouncil.org/educati… #Psoriasis #IPCFellowship

IPC's five-part GPP training builds skills to recognize generalized pustular psoriasis: differentiating it from plaque psoriasis, then scoring severity with GPPGA and GPPASI. Free. Score 80%+ on each assessment for a certificate. psoriasiscouncil.org/educati… #Psoriasis #Dermatology

🇦🇹 Join IPC at EADV Congress 2026: At Last! Personalized Medicine for Psoriasis. Sept 30, 08:30–10:00 CEST, Austria Center Vienna. Why do patients with the same PASI score respond so differently? Agenda and registration: psoriasiscouncil.org/event-p… #Psoriasis #EADV2026

Psoriasis is more treatable than ever. The questions now are about what happens after clearance. #IPCCouncilor Wolf-Henning Boehncke, MD, MA, looks past efficacy to toxicity, disease modification, and comorbidities like PsA. psoriasiscouncil.org/resourc… #Psoriasis #Dermatology

Congratulations to #IPCBoard Member Andrew Blauvelt, MD, MBA, who will be honored at NPF's 2027 Commit to Cure Gala (60th anniversary), April 17, 2027, in Washington, DC, with four other leaders in psoriasis care. psoriasis.org/commit-to-cure… #Psoriasis #PsoriaticArthritis @NPF

The GPA's latest newsletter covers research updates, publications, and coordinator news. This issue follows IPC Research Fellow Shir Azrielant, through her @PsoriasisAtlas placement with Christopher Griffiths and Darren Ashcroft. globalpsoriasisatlas.org/en/… #GlobalPsoriasisAtlas

Obesity may be a treatment target in psoriatic disease, not a barrier to response. #IPCBoard Member Lluís Puig, MD, PhD: adding tirzepatide to ixekizumab lifted PASI 100 to 40.6% and weight loss to 69.2%, vs 29% and 9.1% alone. psoriasiscouncil.org/comment… #Psoriasis #Comorbidity

Ten years connecting early-career dermatologists and researchers with the field's leading minds. Applications for the milestone 2027 class close Sept. 30, 2026. Apply: psoriasiscouncil.org/educati… #IPCFellowship

A patient responds well to an IL-17 inhibitor. Then cancer, and the oncologist wants it stopped. A new IPC paper: active malignancy isn't a contraindication to any biologic. IL-17/IL-23 inhibitors are first-line. psoriasiscouncil.org/ipc-pub… #Psoriasis #Dermatology

📰 ICYMI: The August issue of the IPC Psoriasis Review is now available, featuring: Join 12,000+ professionals staying informed with monthly updates on #psoriasis news, research, and education. Read the August issue now: mailchi.mp/psoriasiscouncil/… #PsoriasisNews #IPCNews

🇦🇹 IPC will be in Vienna for #EADV2026. Our symposium, At Last! Personalized Medicine for Psoriasis will be held Sept 30 from 08:30–10:00 CEST at the Austria Center Vienna, Hall E1, Level 0. View the agenda and register: psoriasiscouncil.org/event-p… #Psoriasis #PersonalizedMedicine

Knut Schäkel walks through the STEP-In and GUIDE studies, explaining how epigenetic changes and resident memory T cells drive disease recurrence, and why early intervention gives patients the best chance at sustained remission: psoriasiscouncil.org/resourc… #Psoriasis #ClinicalTrials

🔁 Please join us in welcoming Steven Fakharzadeh, MD, PhD, and Rodrigo Garcia Salinas, MD, as our newest #IPCCouncilors. Together, they extend IPC's reach across the full arc of disease, from skin to joint. psoriasiscouncil.org/ipc-new… #IPCCommunity #PsoriasisExperts

New Phase 3b data from @EliLillyandCo: Taltz + Zepbound sustained gains in disease activity & metabolic markers through 1 yr in adults w/ psoriatic disease & obesity. Wk 52 PASI 100: 40.5% vs 29.1% alone. ACR50: 43.7% vs 15.7%. investor.lilly.com/news-rele… #Psoriasis #ClinicalTrials

Psoriasis's metabolic effects are now central to care. IPC's new JAAD paper sets five priorities for dermatologists, including screening algorithms and guideline advocacy on comorbidity coverage. Free slide set: psoriasiscouncil.org/wp-cont… #Psoriasis #Comorbidity

Thank you to everyone who joined the IEC–IPC Eczema and Psoriasis Research Incubator. Keynotes, lightning talks, and Challenge Labs made for a morning of real collaboration. Supported in part by @TakedaPharma and @LEOFondet #Psoriasis #ESDR2026 @CouncilEczema